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Multiple sclerosis (MS) is an inflammatory and demyelinating disease of the 
central nervous system (CNS) that results in variable severities of 
neurodegeneration. The understanding of MS has been limited by the 
inaccessibility of the affected cells and the lengthy timeframe of disease 
development. However, recent advances in stem cell technology have 
facilitated the bypassing of some of these challenges. Towards gaining a 
greater understanding of the innate potential of stem cells from people with 
varying degrees of disability, we generated induced pluripotent stem cells 
(iPSCs) from peripheral blood mononuclear cells derived from stable and 
progressive MS patients, and then further differentiated them into 
oligodendrocyte (OL) lineage cells.  We analyzed differentiation under both 
homeostatic and inflammatory conditions via sustained exposure to low-dose 
interferon gamma (IFNγ), a prominent cytokine in MS. We found that all iPSC 
lines differentiated into mature myelinating OLs, but chronic exposure to IFNγ 





was initiated during the pre-progenitor stage. Low-dose IFNγ was not toxic but 
led to an early upregulation of interferon response genes in OPCs followed by 
an apparent redirection in lineage commitment from OL to a neuron-like 
phenotype in a significant portion of the treated cells. Our results reveal that a 
chronic low-grade inflammatory environment may have profound effects on the 
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1.1  Multiple Sclerosis (MS) 
MS is a chronic autoimmune and inflammatory disease that affects the central 
nervous system (CNS). The disease is characterized by an autoimmune 
response directed to myelin, leading to demyelination and disruption of the 
conduction of electrical impulses. Myelin loss ultimately results in axonal 
degeneration, mitochondrial stress and neuronal cell death 1,2. It is the most 
common cause of progressive neurological disability in young adults 3,4 and it 
is estimated that in the US alone nearly one million people suffer from MS, 
affecting more women than men with a gender prevalence ratio of 3:1 5. There 
is no single cause identified as the disease trigger, however there is evidence 
suggesting that genetic and environmental factors contribute to the risk of 





Genetic risk factors include gene variants associated with immune responses, 
such as DRB1*1501 haplotype. Environmental factors include low vitamin D, 
obesity, smoking, and infection by Epstein-Barr virus 4,6.  The disease course, 
outcome, and the response to therapies are highly variable and 
unpredictable7,8.   
 
MS is categorized into four types: Clinically Isolated Syndrome (CIS), 
Relapsing-remitting (RRMS), Secondary Progressive (SPMS), and Primary 
Progressive (PPMS). However, it predominately falls into RRMS and SPMS. 
CIS is the first occurrence of neurological manifestations caused by 
demyelination or inflammation that last at least 24 hours, and it is estimated 
that more than 85% of individuals would progress to RRMS9,10.  This is the 
most common form of MS and is characterized by attacks (relapses) with clear 
and defined neurological symptoms followed by periods of complete or partial 
recovery (remission). Most patients will transition to a SPMS course, where 
there is a worsening of neurological function over time. Approximately 10% of 
patients are affected by PPMS, where symptoms continue to worsen from the 
onset of disease with no periods of remission 3,4,11. While the etiology remains 
elusive, several disease mechanisms have been identified.  
 
The autoimmune attack against myelin is mediated mainly by autoreactive 
CD4+ and CD8+ T cells. B cells play a central role serving as primary antigen-





antibodies.  In fact, in SPMS, there is evidence of B-cell aggregates, or tertiary 
lymphoid tissue, found in the meninges. This fortifies the hypothesis that even 
when MS might start in the periphery, it ultimately establishes strategic sites 
of B and T-cell differentiation and maturation inside the CNS12,13. This CNS’s 
compartmentalized response includes the activation of microglia effectively 
mounting both peripheral and central immune responses14. 
 
Oligodendrocytes, the myelin producing cells, have a key role in disease 
and recovery. The process of remyelination depends on the ability of 
oligodendrocyte progenitor cells (OPCs) to migrate to sites of injury, 
proliferate, and mature to regenerate myelin and provide axonal integrity15. 
While OPCs are present throughout the CNS including areas of demyelination, 
it is thought that about 20% of people with MS remyelinate to some extent, 
though for most MS patients this process is hindered. Remyelination is more 
effective earlier in disease than later, which is when failure to remyelinate 
becomes major contributor to disability16. The reasons behind this failure are 
unknown, therefore it is important to investigate OPCs under both homeostasis 
















1.2 iPSCs to study MS 
Despite the fact that MS was characterized more than a century ago we still 
do not know what causes it and why remyelination fails. Our understanding of 
the disease has been limited in part by the lengthy time of disease progression. 
Another restriction to its study is the inaccessibility of the cells of interest. Most 
of our understanding of disease mechanisms come from animal models, 
postmortem studies, and more recently, imaging techniques such as magnetic 
resonance imaging (MRI).  Animal models, particularly murine models, have 
been critical for elucidating mechanisms of disease and have been paramount 
in advancing drug development 11,17.   While much of this success stems from 
highly conserved similarities between rodents and humans such as origin and 
migration patterns of OPCs, expression of certain transcription factors, 







Recent advances in stem cell technology allow for the generation of OPCs and 
OLs directly from MS patients as they live through the disease, bypassing the 
restrictions of fetal and postmortem studies, and interspecies differences that 
stem from animal models.  
 
iPSC-derived OPCs from MS patients allow for the study of their basic biology 
and/or inherent susceptibilities, and provide a window into how these 
susceptibilities may reflect in the ability of iPSCs to fully differentiate. We can 
also model specific aspects of MS pathology and study how OPCs respond to 
those conditions, enhancing our ability to understand disease progression. A 
distinct advantage of using human iPSC-derived OPC/OL is the ability to bring 


















1.3  Thesis Statement 
Two of the many challenges in MS are the unpredictable outcomes of 
neurodegeneration and failure to remyelinate. It is still unknown why some 
people remain stable through the course of the disease, while others quickly 
progress to disability. To gain a better understanding, we studied the ability of 
iPSCs derived from MS patients with varying degrees of disability to fully 



















iPSCs from people with MS can 
differentiate into 
oligodendrocytes in a 
homeostatic state but not an 
inflammatory milieu 
2.1 Introduction 
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the 
central nervous system (CNS) that has become the most common cause of 
progressive neurological disability in young adults. While the etiology of this 
disease remains unknown, data suggest that it likely involves a combination 
of genetic, immunological, and environmental factors, all of which may 
influence pathology, symptomatic presentation, and disease course and 
outcome 3. Despite having been characterized more than 100 years ago, its 
pathophysiology remains elusive 7, and both the clinical course and disease 
outcome are highly variable 4,8. 
 
Many disease-modifying therapies have been developed to combat 





have thus far been unable to stop or prevent neurodegeneration in its 
progressive phase 19.  One feature of MS that has recently come into focus 
for new therapeutics is the potential to repair demyelination. Despite the fact 
that the adult CNS has an available pool of oligodendrocyte progenitor cells 
(OPCs), and a single oligodendrocyte (OL) has the capacity to produce 40 
myelin segments 20, remyelination in patients with MS is still incomplete. 
One study showed that only approximately 20% of patients are thought to 
remyelinate to some extent 8, but the mechanisms separating successful and 
failed remyelination are not well known 16, even when the progenitors of 
myelin-producing cells are present at the sites of injury15,21.  
 
For OPCs to contribute to remyelination, they likely must migrate to the sites 
of injury, proliferate, and differentiate into OLs22. Each of these processes 
can be inhibited by cytokines (e.g., IL-6, IL-17, osteopontin, IFNγ, TNFα), 
chemokines (e.g.,CXCL1, CXCL2, CXCL10, CXCL11), cytolytic proteins 
(e.g.,lymphotoxin-a and perforin), and signaling factors (e.g., astrocyte-
derived endothelin-1 (ET-1), all of which are known to be present at 
demyelinated areas 23–28, thereby establishing a potentially challenging 
environment for repair.  MS is notably heterogeneous but can be broadly 
categorized into two subtypes, relapsing remitting and progressive MS, 
depending on the presentation and course 
3,4
.  Within both subtypes is a 
wide range of disease severity, with some people exhibiting a stable course 





accumulation of severe disability. The mechanisms responsible for these 
varying outcomes are unclear, and whether there are innate differences in 
the ability to repair remain to be fully understood.  
 
We thus sought to evaluate the potential of iPSCs from people with varying 
degrees of disability to differentiate into OLs, and to determine mechanisms 
that might contribute to failure to differentiate into myelinating 
oligodendrocytes. Thus, we established a platform to generate and 
investigate OL lineage cells by employing a relatively recent stem cell 
technology that allows de- differentiation of peripheral blood mononuclear 
cells (PBMCs) from adult donors into iPSCs which can then be followed by 
differentiation into multiple cells of interest, including OPCs 29–32.  Using this 
system, cells from multiple patients can be simultaneously generated. The 
ability to study human cells, particularly from people with disease, adds an 
important element to the study of MS. While much information on OPC 
biology and differentiation has been generated in rodent developmental 
systems that provide a framework for complementary human studies, some 
critical notable differences may be relevant to human disease. For example, 
most rodent studies utilize OPCs from neonatal animals during a 
developmental state, and OPCs from adults exhibit at least some different 







Rodent cells differentiate in a matter of days, while human cells require 
months in culture, thereby allowing a time scale that is much more reflective 
of humans and allows chronic exposure to varying conditions. Further, 
rodent cells are typically obtained from healthy pups, which may not be 
reflective of disease states, and are from homogeneous donors. We thus 
developed an in vitro platform in which iPSCs were generated from PBMCs 
of people with either stable MS with low disability score or progressive MS 
with high disability score. These cells were then differentiated into mature 
OLs. 
 
During the course of culture, the cells were analyzed both in a non- 
inflammatory/homeostatic state and in an inflammatory environment to better 
reflect a disease milieu. Specifically, to model an inflammatory environment, 
we exposed developing OPCs to interferon gamma (IFNγ), which is a 
cytokine of particularly high relevance in MS. IFNγ is secreted by T cells, 
natural killer cells, and myeloid lineage cells and is often present in MS 
lesions 36,37. Rodent studies in both in vivo and in vitro settings have 
demonstrated that in addition to its pro-inflammatory properties, IFNγ also 
inhibited the differentiation of OPCs into mature OLs, caused cell death 
through multiple pathways  38–40, and affected remyelination through 
endoplasmic reticulum stress 41. The net result of these combined effects 






In support of these hypotheses, the results of our present studies show that 
iPSCs from both stable with low disability and progressive with high disability 
MS patients were able to differentiate into mature, myelinating OLs but that 
chronic exposure to low dose IFNγ early in development had a profound 
negative effect on differentiation. These results demonstrate the ability of 
iPSCs from heterogeneous states of disease to differentiate into OLs in the 
absence of inflammation. Our findings also illustrate the implications of long-
term exposure to even very low concentrations of IFNγ, and highlight the 
importance of evaluating both cytoprotective and remyelination-promoting 
agents in the context of an inflammatory microenvironment that may 










Patients and cells: 
PBMCs were obtained from donors with full informed consent and under 
a n  Institutional Review Board protocol and institutional Stem Cell Oversight 
committee approved protocols. Patients were evaluated in the MS Clinic and 
categorized for disease severity based on their expanded disability status 
scale (EDSS) score and disease duration. Patient pairs were selected to match 
for age, sex, and duration of disease greater than 20 years but to be 
discordant for EDSS low (<3.0) or EDSS high (>6.5). Three stable, three 
progressive and four healthy controls were used in these studies. PBMCs 
were isolated via Ficoll and stored in liquid nitrogen until use. 
 
Reprograming and Characterization of Human iPSCs 
Cryopreserved PBMCs were thawed for culture and reprogrammed to iPSCs 
via transduction of episomal vectors containing Oct3/4, Sox2, Klf4 c-Myc, and 
Bcl-xl factors4 2 – 4 4 . Generated iPSC lines were cultured and expanded in 
E8 medium with recombinant human vitronectin proteins 44,45. The iPSCs 
were characterized by cytology, karyotype analysis, and flow cytometry 







Cell colonies after reprogramming displayed human iPS cell morphology and 
abundant expression of TRA- 1-60, a commonly used marker of 
undifferentiated pluripotent human stem cells. Generated iPSC lines also 
exhibited normal karyotype by standard G-banding (300-500 bands) 
karyotyping method 46–48. 
 
Differentiation of iPSCs-derived OPCs and OLs 
Human iPCS were differentiated to OPCs and OLs as previously described 49, 
with minor modifications of cell density. 
 
Cell Sorting 
Cells were sorted based on expression of either PDGFRα or O4, depending on 
the experiment and maturation state of the cells. For PDGFRα expression, 
cells were sorted after 56 to 60 days of culture. For O4 expression, cells were 
sorted at approximately day 75. Cells were dissociated to a single cell 
suspension with TrypLE , filtered, Fc blocked with True Stain FcX (1:20, Cat 
# 422302, BioLegend), then stained with either PDFGRα/CD140a (1:10 Cat# 
323506, BioLegend) or O4 (1:50 Cat # 130-117-357, Milteny), and cell density 
was adjusted for sorting. Sorted cells were placed in culture to recover and 








Immunofluorescence (IF) characterization 
After sorting, cells were cultured until analysis and then were fixed with cold 
4% paraformaldehyde for 20 minutes, permeabilized with 0.2% TX-100 in 
1X PBS for 20 minutes, blocked with 3% NGS and 0.1% TX in 1X PBS 
for an hour. MBP primary antibody was used at 1:500 dilution in blocking 
buffer and incubated at 40C overnight, followed by washing and incubation 
with secondary goat anti-mouse Alexa Fluor® 488 (1:500) for 2 hours in 
blocking buffer. Nuclear staining was conducted with 1µM DAPI, incubated 
for 20 minutes in PBS. All steps with the exception of the primary antibody were 
performed at room temperature. 
 
Cytokine treatment 
Bulk OPC cultures were treated with recombinant human IFNγ (PeproTech) 
at a dose of 10 ng/ml from day 36 to day 82-85 or from day 60 to day 82-
85, with a change of medium every 48 hours. 
 
Flow cytometry analysis 
Cells were prepared as described above, followed by staining with 
antibodies for cell surface markers, PDFGRα/CD140a (1:10, Cat #323506, 
BioLegend), O4 (1:50, Cat # 130-117-357, Miltenyi Biotec), and GLAST 
(ACSA-1) (1:10, Cat # 130-095-814, Miltenyi Biotec). Viability was 







For intracellular staining, cells were fixed and permeabilized with the Foxp3 
transcription factor staining buffer kit (Cat # 00-5523-00, eBioscience) 
according to the manufacturer’s protocol, followed by staining of the 
intracellular marker Olig2 (1:50, Cat # MABN50A4, EMD Millipore). 
 
Co-culture of Neurons and OPCs 
Cultured cells were harvested at day 84 and were seeded in one of two 
compartmentalized chambers, which are separated by micro-channels as 
previously described 50 at density of 10,000 cells. The second chamber was 
seeded with neurons, generated from hESC (H9 cell line), and the axons from 
the neurons protrude through the micro-tunnels, providing a substrate for the 
myelinating OLs. Approximately 30 days later, cells were fixed with ice cold 
4% paraformaldehyde for 20 minutes followed by washing with 1X PBS. 
Cells were then blocked with 3% normal goat serum and 0.1% Triton-X in 
PBS for 1hour, and stained with primary antibodies of mouse SMI99 MBP 
(1:50, Cat#SMI-99P, Covance), chicken NF (1:200, Cat# NF-M, Aves Lab 
Inc), and rabbit GFAP (1:1000, Cat#Z0334, Dako), overnight at 4
o
C. 
Samples were washed three times after incubation with primary antibody 
with 1X PBS, and then appropriate secondary antibodies conjugated with Alexa 
Fluor (488 mouse, 555 chicken, and 647 rabbit, all at 1:250, Invitrogen) were 





Cells were incubated for 5 minutes with 1μM DAPI (4′, 6-diamidino-2′- 
phenylindoldihydrochloride; Invitrogen) as a nuclear counter-stain.  
Zeiss live-cell inverted microscope (Axio Observer; Zeiss, Germany) was used 
for imaging at 20X magnification.  
 
Quantitative PCR 
RNA was isolated via an  RNeasy kit (Qiagen) followed by cDNA 
preparation with a n  iScript cDNA Synthesis Kit (Bio-Rad). Reactions were 
conducted with iQ SYBR Green Super Mix (BIO-RAD) with primers 
manufactured by Integrated DNA Technologies (Coralville, IA, USA). Primer 
sequences were: Human GAPDH (Forward 5’-AAG GTG AAG GTC GGA 
GTC AAC-3’, Reverse 5’- GGG GTC ATT GAT GGC AAC AAT A-3’), Human 
MBP (Forward 5’-CTA TAA ATC GGC TCA CAA GG-3’, Reverse 5’-AGG 
CGG TTA TAT TAA GAA GC-3’). 
  
RNA sequencing 
OPC cultures were FACS-sorted for expression of PDGFRα as above, re-
plated and cultured with or without the addition of 10 ng/ml of IFNγ for 16 
hours, followed by RNA isolation (RNeasy Plus mini kit, Qiagen). Libraries 
were prepared using the Illumina TruSeq Stranded Total RNA LT Sample 








Transcript counts were quantified by pseudo-alignment against the human 
transcriptome (GRCh38.p13) using Salmon v1.1.0 51, after filtration of 
ribosomal RNA transcripts using BBSplit. Raw counts were imported into R 
v3.6.2 and aggregated to gene level counts with tximport v1.14.0 52 and then 
DESeq2 v1.26.0  53 was used to normalize, perform exploratory analysis, and 
test for differential gene expression. Volcano plots were generated with the 
Bioconductor package EnhancedVolcano 
v 1 . 4 . 0 (https://github.com/kevinblighe/EnhancedVolcano). The functional 
analysis was generated through the use of Ingenuity Pathway Analysis 
(Qiagen) using thresholds of adjusted p value<0.05 and Log2 FC less than -1 
or greater than 154. The shell scripts and R script used to quantify and analyze 
are available upon request. Raw and processed data are publicly available: 
(GEO; https:/www./ncbi/nlm/nih/gov/gds) with accession number GSE147315. 
 
Transmission Electron Microscopy (TEM) 
Cells were fixed in 2.5% glutaraldehyde, 3mM MgCl2 in 0.1 M sodium 
cacodylate buffer, pH 7.2 for one hour at room temperature. Samples were 
then rinsed and postfixed in 1% osmium tetroxide, 0.8% potassium 
ferrocyanide in 0.1 M sodium cacodylate for 1-2 hours on ice in the dark. The 
samples were then rinsed in 100 mM maleate buffer, followed by incubation 
with uranyl acetate (2%) in 100 mM maleate for 1 hr in the dark and then were 





Eponate 12 (Ted Pella), then polymerized at 370C for 2-3 days followed 
by incubation at 600C overnight. Thin sections, 60 to 90 nm, were cut 
with a diamond knife on the Reichert- Jung Ultracut E ultramicrotome and 
picked up with 2x1 mm formvar copper slot grids. Grids were stained with 
2% uranyl acetate in 50% methanol followed by lead citrate and observed 
with a Philips CM120 TEM at 80 kV. Images were captured with an AMT 




A statistical analysis was conducted on the percentages of cells 
expressing O4 or Olig2 between and among controls and MS patients 
(categorized as stable or progressive) with and without IFNγ treatment 
(untreated, at day 36 and at day 60) using generalized estimating equations 
(GEE) to account for inclusion of multiple samples per patient. Statistical tests 
were two-sided, and significance was determined using a p-value less than 










 iPSCs successfully differentiated to mature OLs 
PBMC-derived iPSCs were validated as described in methods and then 
cultured under a standard protocol to generate OL lineage cells. The 
progression of differentiation occurs over a lengthy time period of 80-90 days 
for full maturation (Fig 1). This process is shown in a sample phase contrast, 
which demonstrates the morphologic change associated with differentiation 
to oligo lineage cells in Fig 2. To more definitively validate the identity of the 
oligo lineage cells, we intensively characterized them using a variety of 
complementary methods. Throughout the culture period, we monitored cells 
for expression of canonical markers, transcription factors, and ultimately, the 
critical evidence of OL lineage, namely production of myelin and functional 
wrapping. Specifically, we characterized the phenotype of our cultures at 
distinct time points (OPCs, immature and mature OLs), to monitor 
development. Towards the end of cultures (approximately days 80-85) as 
cells are reaching maturity, we analyzed cells for the expression of 





As Olig2 is a critical transcription factor for the development of OLs, and 
MBP is the hallmark of a mature OL, we analyzed these in depth. As shown 
in Fig 3A, cells express both of these markers. OLs exhibit a characteristic 
morphology in their mature state, and Fig 3B shows highlighted OLs with 
both this morphology and a concomitant expression of MBP. These figures 
help to confirm the identity of the cells.  
To validate the expression of O4, cultures were first sorted by FACS based 
on the expression of O4 and placed them in culture to mature fully. After 
culture, cells were then immunostained with O4. As shown in Figure 3C the 
cells retained expression through maturity, validating both the expression of 
the marker and the antibodies used for analysis. The critical function and 
hallmark of OLs is the production of myelin and wrapping of axons. We 
therefore assessed this process in different formats. 
 
To assess myelination of axons, OL cultures were replated in a split chamber 
system, in which the OLs were plated in one chamber and neurons were 
cultured in a separate chamber, while their axons are allowed to migrate 
through microtunnels into the OL chamber. After approximately 30 days of 
co-culture, the chambers were subjected to immunofluorescence (IF) analysis 
with antibodies to MBP and neurofilament (NF). As shown in figure 3D, 
mature OLs were able to contact and apparently ensheathe axons. To conduct 
an ultimate identification of wrapped axons, we employed electron 






Figure 3E shows representative images of myelinated axons with compact 
lamellar myelin. Similar results were obtained from all donors. As a further 
confirmation of the identity of the cells, we conducted qPCR analysis for MBP 
expression, which provides a specific genetic confirmation of expression of this 
hallmark molecule. As shown in Figure 4, OLs had a high level of expression 
of MBP. Taken together, these data show that iPSCs from MS patients 
differentiated into OPCs, which then could be further differentiated to 
functionally mature OLs.   
 
iPSCs from all patients differentiated into OLs 
Having validated the experimental process and identity of the cells, we next 
conducted a more high-throughput and quantitatively comparable analysis of 
the generation of OLs from iPSCs. To this end, we cultured and differentiated 
iPSCs from the six patients and four healthy controls, for approximately 85 
days to a mature OL stage, and then profiled large populations by flow 
cytometry using O4 and Olig2 as identifying markers. O4 has been used to 
identify and characterize oligo lineage cells from tissue of healthy individuals 
and from chronic lesions of MS patients 55,56. All MS iPSC lines expressed 
O4, albeit to different extents, which were similar to those reported previously 
32.  The results of these analyses showed effective differentiation of all 
samples, with a broad range of efficiency of differentiation and maturation 





efficiency of differentiation for each donor. 
 
Some cell lines demonstrated higher degrees of variability than others, but 
neither variability nor final efficiency of maturation was statistically linked with 
one cohort (Figure 5A). In order to compare among groups, we analyzed the 
averages of each group with donors of each cohort combined (Figure 5B). 
While there was a trend to lower efficiency in the progressive group compared 
to healthy controls, there was no significant difference in the aggregates. We 
similarly analyzed the comparison of Olig2 expression, with similar results 
(Figure 5C), in which a trend towards a decrease in progressive samples 
was present, but it did not reach significance. Taken together, these results 
demonstrated that iPSCs from all donors could ultimately differentiate into 
mature OLs. 
 
Chronic exposure to low-dose IFNγ inhibits OPC 
differentiation 
An important consideration in myelin repair in a chronic disease is that the 
CNS may not be in a homeostatic state in MS, and that either overt or 
smoldering inflammation may be present. To investigate the effects of an 
inflammatory environment on the differentiation of iPSCs into OPCs, we next 
assessed the process in the presence of sustained exposure to low-dose 
IFNγ. Parallel cultures of untreated and treated cells were established, with 





day 36 to final analysis , or for some experiments from day 60 to final analysis. 
At the end of culture, cells were analyzed by flow cytometry for differentiation 
markers as established in figures 4 and 5.  
 
Figure 6 shows the results of differentiation of each individual MS patient, with 
and without IFNγ. Figure 7A shows a combined analysis of progressive, 
stable and healthy control comparisons, and figure 7B shows the effects of 
IFNγ treatment on the differentiation of the donors, separated by groups, with 
replicates for each donor averaged. As shown in the graphs, IFNγ treatment 
initiated early during culture profoundly inhibited the development of O4+ OLs 
in all groups.  While iPSCs from some patients differentiated more efficiently 
than others, the inhibition was uniformly robust, regardless of the nature of 
disease in the donor. The culture requires a lengthy process, and as cells 
transition through phases of progenitor plasticity during the course of 
differentiation, we sought to determine whether IFNγ exposure might produce 
different effects on cells that were not treated until they had reached the early 
OPC stage. Interestingly, the inhibitory effects were significantly milder when 
treatment was delayed to day 60, highlighting a critical period of vulnerability 
during the early stages (Figures 6-7). A similar effect was observed on the 
expression of Olig2, a transcription factor necessary for activation of the 
genetic program of OLs (Fig 8), again supporting the inhibitory effect of IFNγ 






As a genetic confirmation of the impact of  IFNγ  on terminal differentiation, an 
analysis of MBP expression  demonstrated that while untreated cells had high 
levels  of MBP, consistent with mature OL status, those that were exposed to 
IFNγ had minimal detectable levels, furthering the evidence that OL 
development was inhibited (Figure 9).   
In sum, these data, along with the data from Figures 4-5, show that iPSCs 
from all groups effectively mature to OLs, but exposure to IFNγ significantly 
derails this process. 
 
Sustained exposure to low dose IFNγ does not restrain 
cells at OPC stage but rather redirects lineage phenotype 
Consistent with previous studies, we observed no overall increase in cell death 
in treated cultures, even when cells were exposed to low-dose IFNγ during the 
high vulnerability period from day 36 to 60 (Figure 10). Thus, in order to 
account for the decrease in OLs, we evaluated other populations to identify 
one with a concomitant increase. Previous rodent studies showed that IFNγ 
treatment of progenitors led to an increase in PDGFRα progenitors and a 
decrease in mature OLs by overriding cell cycle exit 39. We thus quantified 
PDGFRα expression at the end of the cultures, but did not find a universally 






As expected at this timepoint, PDGFRα expression was low in untreated 
cultures, as OPCs have matured into OLs and thus lost expression by this 
phase. Treatment with IFNγ did not increase the fraction of cells expressing 
PDGFRα, with the exception of the progressive samples, which while 
reaching a low level of significance, the percentage of all remained very low 
(<5%) and thus could not compensate for the loss of the large OL population 
(Figure 11).  
 
As astrocytes commonly arise from mixed cultures, another possibility was 
that IFNγ treatment skewed early cells towards an astrocytic profile. To 
quantify percentages of astrocytes we performed flow cytometry analysis 
using the GLAST (ACSA-1) marker. Our results showed IFNγ exposure 
significantly reduced this population as well (Figure 12).  
 
As development of OL and astrocyte lineages was suppressed, we next 
investigated the development of neuronal lineages in the presence of IFNγ, 
via expression of βIII tubulin (TUJ1). In sharp contrast to the suppressive 
effects on astrocyte and oligo lineages (Figures 12-13A), IFNγ exposure led 
to a concomitant, significant increase in the percentages of cells expressing 
TUJ1, with similar patterns linked to time of exposure (i.e., from day 36 or 








Short-term IFNγ treatment upregulates immune response 
pathways. 
To better understand the effects of IFNγ treatment on OPC differentiation, we 
sought to monitor early transcriptional changes through RNA sequencing. To 
this end, PDGFRα+ cells were sorted at the OPC stage (day 60), allow to 
recover in culture, and then treated for 16-hour with low-dose IFNγ. We 
found a pronounced effect on the transcriptome of OPCs with over 3200 
differentially expressed genes; 1749 were upregulated and 1453 
downregulated (Figure 14A-B). The most induced and highly significant 
genes were largely those traditionally associated with an inflammatory 
response such as TAP1, CXCL9, and CD74 (Figure 13B, Table 1). Among 
the highly upregulated genes, we found early interferon response genes: 
STAT1, IRF1, IRF2, IRF7, and IRF9, peptide processing genes: TAP1, TAP2, 
and ERAP1, immunoproteasome component genes:  PSME1, PSME2, 
PSMB8, and PSMB9, antigen presentation genes class I: HLA-A and HLB-
B, and class II: CIITA, (Figure 14C, Table 1). 
Consistent with these findings, functional analysis of differentially regulated 
genes showed most significant enrichment for antigen presentation and 
immune activation (Fig 14D). In their rodent studies, Chew et al., 2005 
showed that IFNγ kept OPCs in the progenitor state by overriding the cell-
cycle exit, which they demonstrated by showing upregulation of cell-cycle 






Our results did not show a similar differential expression of cell-cycle genes 
(Figure 14C), indicating that a different mechanism may be operational at 
this timepoint in human cells. Consistent with suppression of OL 
development, however, upregulation of DAAM2, which was recently shown 
to play a role in suppressing OPC differentiation but has not previously been 
linked with IFNγ signaling in OPCs 57, was observed (Log2FC = 1.97, 
adjusted p value = 3.73E-07 ). Thus, treatment of progenitors at the 









The results of our studies revealed a number of novel and intriguing findings 
that may help to advance the development of strategies for neuroprotection 
and/or repair. Because of the inaccessibility of cells of interest in MS and the 
long course of disease development, creating platforms to study human cells 
derived from different patients will be critical to these advances. In order to 
generate a relatively high throughput system that allows intensive 
investigation of these cells, culture systems have been established, and initial 
results have reported the feasibility of differentiation into functional OLs from 
iPSCs.  
Both intermediate OPCs and mature OLs were generated from people with 
MS as well as from healthy controls. Importantly, in addition to the 
demonstration of an OL phenotype, the cells were shown to successfully 
myelinate a shiverer mouse, an animal model that cannot form compact 
myelin due to MBP deficiency20. Consistent with these reports, our data also 
showed that iPSC from people with either stable/low disability or 
progressive/high disability MS differentiated into OPCs and OLs, expressing 
canonical markers that span the timeline of development and ultimately 






OPCs have been identified at the site of MS lesions, and the apparent ability 
of progenitors to mature contributes to the great remaining mystery of why 
the process of remyelination fails, and as a corollary why treatments to 
promote remyelination have not achieved greater success in human trials 
58
 
despite promising animal modeling 33,59. 
 
One critical factor that is often not considered in the drug screening process 
or in vivo models is the diseased environment. The local milieu includes 
secreted cytokines by invading cells as well as by resident diseased cells 
that affect balance of anti- and pro- inflammatory signals, growth factors and 
debris clearance 60,61. For example, recent studies have shown that iPSC-
derived neural progenitor cells (NPC), from people with primary progressive 
MS (PPMS) did not provide adequate trophic or protective support for rat 
OPCs in culture 62. Additional work from the same group later showed that 
diseased NPCs highly upregulated senescence genes, with HMGB-1 as a 
potential culprit in the failure of diseased NPCs to support rat OPC growth, 
from both local and migrating cells 63. 
 
In addition to the absence of trophic effects, the disease environment is also 
challenged by the presence of inflammation, which is a prominent feature in 
early-stage MS. An array of proinflammatory cytokines have been implicated, 





is increasingly recognized as a driving factor in the pathology for its ability to 
amplify an inflammatory response by orchestrating the upregulation of CCL5, 
MIF, and CCL27 cytokines via activation of astrocytes and T-cells 65. The 
effects also prevent OPC differentiation and remyelination, in part because 
IFNγ foments a hostile environment that is not conducive to regeneration by 
inducing cell death (at high concentrations) i.e. STAT1/IRF-1 pathway 36, 
inhibiting cell cycle exit 39, and inflicting endoplasmic reticulum stress 41.  
 
To mimic an inflammatory disease-type environment, we sought to 
investigate effects of chronic exposure of low-dose IFNγ on our cultures. In 
a long-term culture setting, a very low dose was sufficient to dramatically 
inhibit the maturation of OLs, and the earlier the phase of culture and the 
longer the cells were exposed, the greater the effect. Our studies are 
consistent with previous findings in that IFNγ has a milder effect on immature 
rodent OLs, and a minimal effect on mature OLs 38,66. The mechanisms 
behind this difference remains unclear, but highlights a critical vulnerable 
stage of development. Consistent with previous studies demonstrating that 
low-dose IFNγ did not promote apoptosis 39, our data also indicated no 
difference in cell death between untreated and interferon groups, which 
suggests that at least in low levels of inflammation, killing of the OPCs may 
also not be the primary cause of failure to remyelinate. It is interesting to 
speculate that the profound inhibitory effect that IFNγ exerts on OPC 





setting. The presence of OPCs at the sites of injury 15,21 and evidence of 
early remyelination in MS 16,67 strongly suggest that the capability to replace 
OLs and repair myelin is present. One possibility thus is that OPCS do 
migrate properly to site of injury to begin the repair process, but ultimately 
are halted in the differentiation process by the presence of a pro-
inflammatory environment, and the effects of even low-dose cytokine could 
be sufficient to effectively shut down the repair process, in theory.  
 
IFNγ is a potent and pleiotropic cytokine that has been shown to affect 
mitochondrial function, which is considered a cause of axonal degeneration 
that accompanies failed remyelination 68,69. Interferon also induces oxidative 
stress, which in turn can cause DNA damage 1.  A significant implication of 
these data is that screening strategies to discover agents to promote 
endogenous differentiation may benefit from considering their effects under 
chronic low-grade inflammation, since therapies that promote OPC 
differentiation and/or survival in a homeostatic state may not be as effective 
in the presence of inflammatory molecules, and testing in the presence of 
such an environment may help to identify more potent and effective agents. 
It is becoming clearer that progenitors of most cell types are not unalterably 
committed to a linear and unwavering path but rather may be influenced by 
environmental conditions, including growth factors and cytokines.  In support 
of this notion, for example, previous work showed that IFNγ inhibited 





mature O1+ oligodendrocytes, while enhancing proliferation of immature 
OPCs 39.  Our data is consistent with the suppression of maturation, but in 
our long-term culture of human cells, there was neither retention nor selective 
proliferation of early progenitors overall, but rather, the acquisition of a 
neuronal phenotype in at least a portion of cells. This finding parallels a 
previous discovery in microglia, in which exposure to a low-dose of IFNγ led 
to the acquisition of a neuronal- like phenotype 70. Consistent with these 
findings, another report showed in vitro that IFNγ induced neuronal 
differentiation of neural stem cells in a dose-dependent manner. Together, 
these data support the notion that IFNγ inhibits the development of oligo 
lineage cells while promoting the differentiation into a neuronal lineage 71.  
 
This prevalent plasticity in various cell types in response to the environment 
highlights a critical point in the ability of cells to adapt to changing 
circumstances and local influences and possibly serve different roles under 
conditions of disease or infection, for example.  One hypothetical 
consequence of such plasticity is that as cells convert to different 
phenotypes, the availability of functional cells needed to repair could be 
depleted.  If the OPCs and progenitors follow a different lineage pathway, 
then they would be unavailable to become OLs in this setting, for example.  
numerous lines of evidence indicate the ability of progenitor cells to acquire 







As a means to begin to gain a greater understanding of the transcriptional 
basis for reprogramming in people, we undertook a transcriptomics analysis 
to identify genetic patterns of expression in a homeostatic and IFNγ-exposed 
states. The baseline genetic profile confirmed the identity of the PDGFRα 
sorted cells as OPCs. Interestingly, IFNγ exposure led to the differential 
expression of a number of genes in diverse pathways. Consistent with our 
observed effects on decreased myelin production, our screen identified an 
upregulation of one gene of interest, DAAM2 (Dishevelled Associated 
Activator of Morphogenesis 2), a Wnt signaling downstream effector. DAAM2 
suppressed remyelination after white matter injury in rodents and humans 57, 
suggesting that this pathway may be a possible candidate for genes that 
could theoretically contribute to the observed effect. 
 
Another study demonstrated a correlation between decreased DAAM2 
expression and improvements in remyelination in Guillain- Barre syndrome 
72, suggesting that IFNγ may activate specific pathways redirecting the 
process. DAAM2 is also thought to be important for dorsal patterning in the 
development of the spinal cord 73, which is also consistent with these findings. 
Further investigation into the significance of this pathway in this setting would 
be necessary to parse out its function, however, but it is interesting to 
speculate that activation of specific programs of gene expression by cytokine 





function into an immune/inflammatory realm has been recently identified as 
well. Specifically, rodent OPCs exposed to IFNγ acquired properties typically 
associated with the immune system. Termed “inflammatory OPCs” these 
IFNγ–exposed cells upregulated molecules such as MHCs and further took 
on antigen presenting cell characteristics 74,75.  The implications of this process 
are profound, in that it suggests the possibility that OPCs at the site of a 
lesion could convert to an immune-like cell that stimulates cytotoxic T cells 
and perpetuates a damaging immune response, while similarly converting 
away from a cell type designed to repair damage. Our transcriptomics 
analysis demonstrated this conversion on at least the RNA level in all of the 
samples we tested. Our present data showed upregulation of interferon 
response genes such as STAT1, IRF1, IRF2, IRF7, and IRF9, all of which 
could contribute to the perpetuation of an inflammatory phenotype.   
 
Aligning with the possibility of acquisition of antigen presenting cell 
characteristics, IFNγ also led to upregulation of peptide processing genes of 
importance to the immune system, including TAP1, TAP2, and ERAP1, along 
with the immunoproteasome genes PSME1, PSME2, PSMB8, and PSMB9. 
Further, MHC molecules necessary for antigen presentation including class 
I HLA-A and HLB-B, and class II CIITA were all highly upregulated in 
response to IFNγ. These results have intriguing implications in a disease 
setting in that it could be a means by which OPCs inadvertently worsen 






Gaining a greater understanding of OPC and OL function in people with MS 
is of paramount importance to uncovering mechanisms of disease and 
developing new targeted therapeutics. Taken together, our data demonstrate 
that in a nurturing environment, iPSCs derived from people with stable and 
progressive MS are capable of differentiating into mature OLs, but that this 
process is profoundly inhibited by chronic exposure to low-dose IFNγ. Our 
data have significant clinical relevance as they suggest that the environment 
in which differentiation therapies are administered may profoundly affect the 
efficacy of the treatment, and ultimately, a combination approach of 
decreasing inflammation in the CNS may be necessary for OPC 













Table 1. RNA-seq analysis of gene enrichment of IFNγ exposure in 
PDGFRα sorted OPCs. 
Gene Log2 FC p-adj 
IDO1 14.83555 8.17E-53 
CXCL9 13.76216 1.18E-47 
APOL1 11.90543 2.27E-32 
GBP4 11.72463 1.44E-56 
CXCL11 11.47197 1.15E-48 
LGALS17A 10.60319 1.66E-20 
XAF1 10.42001 5.05E-20 
OAS2 10.10588 7.54E-75 
CXCL10 10.05021 7.80E-116 
GBP1P1 9.55261 1.86E-56 
BATF2 9.54757 5.92E-52 
GBP1 9.28494 3.37E-70 
PLA2G2D 8.77572 3.87E-04 
GBP6 8.58085 6.02E-07 
CIITA 8.44938 1.06E-58 
CEACAM1 8.42068 8.08E-19 
TMEM140 8.39200 2.36E-28 
USP30-AS1 8.33499 1.11E-18 
ACSL5 8.33042 8.93E-12 
GBP5 8.26802 4.57E-80 
Table 1 shows the 20 most upregulated genes detected by RNA-Seq after 
exposure to IFNγ. Differentially expressed genes were sorted by fold change 


















highlighted in Fig 3B. Fig 3C shows the immunostaining of cells that were 
FACS-sorted for the expression of O4 at day 75 of culture, then re-cultured 
for an additional 9 days prior to analysis. As shown, O4 expression remained 
and was confirmed at day 84 of differentiation. To demonstrate functional 
myelination, two different approaches were undertaken. First, OLs at day 84 
of differentiation from mixed cultures were co-cultured in a chamber format 
in which neurons remain on one side, but axons project through micro-
tunnels to the other side where OLs are cultured. After three weeks of co-
culture, cells were immunostained for MBP in green, and neurofilament in 
red. Fig 3D shows OLs contacting axons, with the appearance of wrapping. 
The second approach to validate the functional wrapping was transmission 
electron microscopy (TEM) analysis on OLs from mixed cultures as shown in 
Fig 3E. All images are representative samples encompassing all cell lines. 




















Figure 5. iPSC lines from all donors differentiate to OLs. To quantify and 
compare the differentiation of iPSCs into OL lineage cells from multiple donors 
in a more high-throughput manner, flow cytometry analysis was employed. 
Based on the validation in figure 2, O4+ and OLIG2+ expression was 
determined in cells from mixed cultures at approximately day 85 of 
differentiation. 5A shows the percentage of O4 expression for each of the 
four healthy controls (HC1-4), and MS donors classified as stable (S1-3), and 
progressive (P1-3).  Each dot representing one experiment per donor. Number 
of experiments per donor: HC1=6, HC2=3, HC3=6, HC4=2; S1=5, S2=7, 
S3=5; P1=10, P2=6, P3=4. 5B shows the compilation of the data in Fig 5A, with 
the samples from each group combined and averaged.  As in Fig 5A, the data are 
comprised of four healthy controls, three stable, and three progressive donors. 
Each dot represents the average for one donor.  5C the compilation of the data 
of expression of Olig2 per group, with each dot representing one patient (not 
all samples were analyzed for Olig2). Number of donors per group: HC= 2, 
S=3; P=3, with 3-6 experiments per group. Significance was determined with 


















Figure 7A. Combined expression of O4 from both MS groups, alongside the 
combined HC group, all treated at either day 36 or 60 as noted. The control 
group consists of four donors with 11 to 14 experimental replicas, the stable 
group consists of three donors with 3 to 14 experimental replicas, the 
progressive group contains three donors with 3 to 17 experimental replicas, 
and the. Figure 7B shows the average combined expression of O4 per donor 





















Figure 8A. Combined expression of O4 from both MS groups, alongside the 
combined HC group, all treated at either day 36 or 60 as noted. The control 
group consists of two donors, each with two experimental replicas. The MS 
stable group consists of three donors, two of which have one replica. The 
progressive group consists of three donors. Figure 8B shows the average 
combined expression of OLIG2 per donor in each group. Significance was 
determined with generalized estimating equations with R, and using a p-value 


































































Figure 11. Sustained exposure to low dose IFNγ does not enrich for cells 
expressing PDGFRα. After approximately 85 days of culture, the identity of 
the IFNγ-treated cells was determined by flow cytometry.  11A shows the late-
stage culture expression of PDGFRα for each group in untreated and IFNγ-
treated cells, beginning at either day 36 or 60, as labeled. The healthy control 
group consist of 4 donors, each with 2 replicas; the stable group consists of 
three donors, each with five to eight replicas; the progressive group includes 
three donors with four to seven replicas of each. 11B shows the average 



















Figure 12A. Percentage of cells expressing the astrocyte marker GLAST in 
untreated cells and cells treated with IFNγ, starting at day 36 or 60 of the 
healthy control group. The group consisted of four donors with one to two 
experimental replicas each. 12B shows the average combined expression of 






















Figure 14. RNA-Seq analysis of IFNγ exposure in PDGFRa sorted OPCs. 
OPCs were sorted for PDGFRα expression from a total of 7 different cell lines 
generated from the following donors: 3 people with progressive MS (P1-P3), 
2 people with mild/stable MS (S1, S3), and two healthy controls (HC1, HC3). 






RNA was then isolated and subjected to RNA-Seq analysis as described in 
the methods section. Fig 5A shows a heatmap of all differentially expressed 
genes (defined by having an adjusted p value < 0.05) in two sets: those that 
are upregulated by IFNγ (Log2 Fold Change > 0, n = 1749) on top and those 
that are downregulated by IFNγ (Log2 Fold Change < 0, n = 1453) on the 
bottom for each of the seven OPCs tested, showing patterns of similarity and 
differences between groups and individuals. Fig 5B shows a volcano plot with 
Log2 Fold Change on the x- axis and – Log10 Adjusted p value on the y-axis. 
Each individual gene is represented by a single dot, and color indicates the 
following: Red: >2 fold change and adjusted p value < 0.05, Blue: <2 fold 
change and adjusted p value < 0.05, Green: > 2 fold change and adjusted p 
value > 0.05, and Grey: < 2 fold change and p value > 0.05. Fig 5C shows a 
heatmap of IFNγ response genes and immune/antigen presentation genes in 
the top panel, and a subset of cell cycle control genes previously identified 39 
in the bottom panel. Fig 5D shows the results of an Ingenuity Pathway 
Analysis54 conducted on genes differentially regulated by IFNγ (Log2 Fold 
Change < -1 or > 1 and adjusted p value < 0.05) for canonical pathway 







Conclusion and Future Direction 
3.1 Summary 
iPSCs from six MS donors with varying degrees of disability successfully 
differentiated to mature oligodendrocytes. Chronic exposure to low-dose IFNγ 
starting at day 36 of differentiation inhibits OPC differentiation as seen by the 
drastic decrease of O4, MBP, and OLIG2 expression. The inhibitory effects 
were significantly milder when treatment was delayed to day 60 of 
differentiation, highlighting a critical period of vulnerability during the early 
stages. Sustained low-dose IFNγ redirects lineage phenotype as seen by the 
concomitant decreased expression of O4 with increased expression of TUJ1 
in the healthy controls. Short-term IFNγ exposure on PDGFRα sorted OPCs 
upregulates immune response pathways and molecules such as MHCs, which 










3.2 Future direction 
 
Our results shed light on the importance of the environment in which 
differentiation therapies are administered. The inflammatory milieu recreated 
in our study showed that the disease environment may profoundly 
negatively affect the efficacy of the treatment. Therefore, it would be useful 
for promising remyelinating agents to be tested under these inflammatory 
conditions, which may provide insights into the individual biology of the 
patients. Ultimately, decreasing inflammation in the CNS may be necessary 














Bcl-xl…………………..B-cell lymphoma-extra large 
cDNA………………….Complementary deoxyribonucleic acid 
CIITA…………………..Class II transactivator 
c-Myc………………….Proto-Oncogene transcription factor C-Myc 
CNP……………………2',3'-Cyclic-nucleotide 3'-phosphodiesterase  
CNS……………………Central nervous system 
CXCL#………………...C-X-C Motif Chemokine Ligand  
CCL#............................C-C Motif Chemokine Ligand 
DAAM2………………...Dishevelled Associated Activator Of Morphogenesis 2 
DAPI…………………. .4′,6-diamidino-2-phenylindole 






Fc………………………Fragment crystallizable region 
GAPDH………………..Glyceraldehyde 3-phosphate dehydrogenase 
GLAST (ACSA1)……Glutamate Aspartate Transporter 1 (astrocyte cell 
surface antigen-1) 
GFAP………………….Glial fibrillary acidic protein 
hESC…………………..Human embryonic stem cells 
HLA…………………….Human leukocyte antigen  
HMGB-1……………….High mobility group box 1 protein 
IFNγ……………………Interferon gamma 
IL#……………………..Interleukin 
iPSCs………………….Induced pluripotent stem cells 
IRB……………………..Institutional review board 
IRF#.............................Interferon regulatory factor 
Klf4…………………….Kruppel-like factor 4 
MBP…………………...Myelin basic protein 
MIF…………………….Macrophage migration inhibitory factor 
MS……………………..Multiple sclerosis 
NF……………………...Neurofilament  
NGS……………………Normal goat serum 
NKx2.2…………………Homeobox protein NKx2.2. 
NPCs…………………..Neural progenitor cells 





Oct3/4………………….Octamer-binding transcription factors 3 and 4 
OLs…………………….Oligodendrocytes 
OLIG2…………………Oligodendrocyte transcription factor 2  
OPCs………………….Oligodendrocyte progenitor cells 
PBMCs………………..Peripheral blood mononuclear cells 
PCR……………………Polymerase chain reaction 
PDGFRα………………Platelet-derived growth factor alpha receptor 
PPMS………………….Primary progressive multiple sclerosis 
PSMB#........................Proteasome subunit beta type 
PSME#.........................Proteasome activator complex subunit  
RNA…………………….Ribonucleic acid 
STAT1…………………Signal transducer and activator of transcription 1 
SOX10…………………SRY-Box Transcription Factor 10 
TAP#............................Transporter associated with Antigen Processing 
TNFα…………………..Tumor necrosis factor-α 
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